Skip to content
Clinical Trials – home
The NetherlandsBack to the Netherlands

Clinical trials in Hague – page 45

1 216 clinical trials in Hague, The Netherlands across 3 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

The NetherlandsOur site in the NetherlandsKlinischOnderzoek.nl(opens in a new tab)
Hague at a glance
1 216
clinical trials
  • Research sites3
Type of trial
Recruitment status
Quick filters

1 216 trials in Hague

Open in trial search

Bronchiectasis

Not yet recruiting

A Study of SAR445399 in Adults Aged 18‑80 with Non‑cystic Fibrosis Bronchiectasis

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:SAR445399
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Osteogenesis imperfecta

Not yet recruiting

Phase 2 Study of AGA2115 in Adults with Osteogenesis Imperfecta (COL1A1/COL1A2 Variants) Evaluating Bone Density

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:AGA2115
  • Sponsor:Angitia Inc. Ltd.

Interstitial lung disease+2

Not yet recruiting

Long‑term Safety and Tolerability of Admilparant in Adults with Idiopathic or Progressive Pulmonary Fibrosis

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Admilparant
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Non-small cell lung cancer

Not yet recruiting

Evaluation of recurrence‑free survival with cemiplimab immunotherapy in medically inoperable stage I non‑small cell lung cancer patients

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

Muscular dystrophy

Not yet recruiting

Long-Term Safety and Efficacy of Oral Ribitol in Participants with Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I/R9)

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years
  • Substances:Ribitol
  • Sponsor:ML Bio Solutions Inc.

Heart disease congenital

Not yet recruiting

Safety and pharmacodynamics of cangrelor tetrasodium in paediatric patients with congenital heart disease undergoing percutaneous vascular procedures

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years
  • Substances:Cangrelor Tetrasodium
  • Sponsor:Chiesi Farmaceutici S.p.A.

Cystic fibrosis

Not yet recruiting

Safety and Efficacy of VX-828, Deutivacaftor, and Tezacaftor in Adults with Cystic Fibrosis

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Sponsor:Vertex Pharmaceuticals Inc.

T-cell type acute leukaemia

Not yet recruiting

Evaluating venetoclax with drug combination in relapsed/refractory T‑cell acute lymphoblastic leukemia patients

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Asparaginase
  • Sponsor:Centre Hospitalier De Versailles

Rheumatoid arthritis

Not yet recruiting

ELV001 for Active Rheumatoid Arthritis in Patients with Inadequate Response to Methotrexate and Tumor Necrosis Factor Inhibition

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:ELV001
  • Sponsor:Elevara Medicines Limited

Pancreatic carcinoma

Not yet recruiting

Phase II/III trial of autologous dendritic cells loaded with allogenic mesothelioma lysate in patients with borderline resectable pancreatic cancer

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Autologous dendritic cells loaded with allogenic allogeneic lysate of mesothelioma cell lines
  • Sponsor:Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

A study to evaluate the safety and effectiveness of zampilimab in people with idiopathic pulmonary fibrosis

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Zampilimab
  • Sponsor:Chiesi Farmaceutici S.p.A.

Non-small cell lung cancer

Not yet recruiting

A study to evaluate the safety and effectiveness of petosemtamab and pembrolizumab in adults with non-small cell lung cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Merus B.V.

Other cities in the Netherlands

The busiest research cities in the country

All 101 cities in the Netherlands

Clinical research in Hague

What the registry says about research in the country

01 Leukemia Research

Innovative clinical trials focusing on Acute Myeloid Leukemia (AML) and associated conditions, evaluating targeted therapies in combination with standard treatments.

  • FLT3 Mutation Studies
  • Combination Therapy Approaches
  • Maintenance Treatment Protocols

Research aims to improve survival rates through personalized treatment strategies for newly diagnosed patients.

02 Lymphoma Studies

Comprehensive research on Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma, investigating novel therapeutic combinations and immunotherapy approaches.

  • High-Grade B-Cell Lymphoma Treatment
  • Immunotherapy Consolidation
  • Relapsed/Refractory Disease Management

Studies focus on improving disease-free survival rates using innovative treatment combinations.

03 Targeted Therapies

Advanced research into targeted therapeutic approaches for hematologic malignancies, combining conventional chemotherapy with novel agents.

  • Immunotherapy Integration
  • Consolidation Strategies
  • Risk-Adapted Treatment Approaches

Trials aim to establish more effective and personalized treatment protocols for high-risk patients.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.